Categories: Corporate and commercial, Intellectual Property, Life Sciences, Pharma, Biotech, Startup Desk, Deals & Cases
LASCCO SA, a biomedical-technology company, and Abionic SA, a nanotechnology company, both based at the Biopôle of Lausanne, Switzerland, entered into a licensing agreement with Fapon Biotech, a global leading life sciences company, based in Dongguan, China, for the use of the pancreatic stone protein (PSP) biomarker for sepsis diagnosis in China.
This agreement initiates a strategic cooperation between LASCCO, Fapon and Abionic, LASCCO’s partner since 2015 for the development and commercialization of PSP on Abionic’s abioSCOPE® device, which has been commercially deployed in 20+ countries since 2022 and is already widely used to diagnose ICU patients in several European hospitals.
Under this agreement, Fapon will engage in the development and commercialization of PSP on its chemiluminescent immunoassay (CLIA) analyzer within the Chinese market. This strategic partnership will usher in a significant breakthrough in the medical field, removing barriers to early sepsis diagnosis. Performing PSP testing on high-risk individuals can flag potential sepsis before the onset of clinical symptoms. Early detection enables to rule in / rule out for critical care, to treat in a timely manner which is tightly linked to reduced risks of organ dysfunction and improved survival rates, and to optimize allocation of medical resources.
VISCHER advised LASCCO SA on all legal issues related to the license agreement. The VISCHER team was led by Christian Wyss (Partner, Corporate / M&A) with Pauline Pfirter (Senior Associate, Corporate / M&A), Luzius Zumstein (Managing Associate, Corporate / M&A), Lukas Züst (Counsel, Head of China Desk), and Qinqin Yao (Associate, China Desk).
